Williams Financial LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Williams Financial LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 132,794 shares of the biopharmaceutical company’s stock, valued at approximately $3,655,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Norges Bank acquired a new position in shares of Pfizer during the 4th quarter worth approximately $2,129,927,000. Wellington Management Group LLP increased its holdings in Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after buying an additional 11,099,024 shares during the last quarter. Swedbank AB bought a new stake in Pfizer during the first quarter worth $172,902,000. Pzena Investment Management LLC lifted its stake in Pfizer by 181.6% in the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after acquiring an additional 4,947,000 shares during the last quarter. Finally, Ruffer LLP grew its position in shares of Pfizer by 248.7% in the 4th quarter. Ruffer LLP now owns 5,796,012 shares of the biopharmaceutical company’s stock valued at $166,837,000 after acquiring an additional 4,133,786 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.4 %

Shares of PFE stock opened at $29.27 on Friday. The stock has a market cap of $165.86 billion, a P/E ratio of -487.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.68. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.42. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $29.21 and a 200 day simple moving average of $28.12.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. The company had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. On average, research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.74%. The ex-dividend date of this dividend was Friday, July 26th. Pfizer’s payout ratio is presently -2,799.53%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research analyst reports. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, September 9th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Wells Fargo & Company increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.